Skip to main content
. 2018 May 9;3(3):e653. doi: 10.1097/PR9.0000000000000653

Table 1.

Treatment-emergent adverse events after administration of a single dose of tanezumab in study CL001 or CL002.

graphic file with name painreports-3-e653-g003.jpg